使用多巴胺受体激动剂普拉克索成功治疗丁丙诺啡戒断症状。
A successful treatment of buprenorphine withdrawal with the dopamine receptor agonist pramipexole.
作者信息
Makhinson Michael, Gomez-Makhinson Juliana
机构信息
Department of Psychiatry and Biobehavioral Science, David Geffen School of Medicine at UCLA, Los Angeles, California; Department of Psychiatry, Harbor-UCLA Medical Center, Torrance, California.
出版信息
Am J Addict. 2014 Sep-Oct;23(5):475-7. doi: 10.1111/j.1521-0391.2014.12133.x. Epub 2014 Mar 15.
BACKGROUND
Buprenorphine, used for treating opioid dependence, may have a withdrawal syndrome requiring treatment. Modulation of the dopamine system, which has been implicated in opioid withdrawal, may be a target for withdrawal for opioids such as buprenorphine.
CASE REPORT
A case is reported of a buprenorphine withdrawal syndrome with predominant symptoms of restlessness that were resistant to clonidine and benzodiazepines. It was successfully treated with the dopamine agonist pramipexole.
SCIENTIFIC SIGNIFICANCE
Dopamine receptor agonists may have a place in the treatment of restlessness associated with opioid withdrawal and may have value for the broader spectrum of opioid withdrawal symptoms.
背景
用于治疗阿片类药物依赖的丁丙诺啡，可能会出现需要治疗的戒断综合征。多巴胺系统的调节与阿片类药物戒断有关，可能是丁丙诺啡等阿片类药物戒断治疗的靶点。
病例报告
报告了1例丁丙诺啡戒断综合征，主要症状为烦躁不安，对可乐定和苯二氮䓬类药物耐药。用多巴胺激动剂普拉克索成功治疗。
科学意义
多巴胺受体激动剂在治疗与阿片类药物戒断相关的烦躁不安方面可能有一席之地，对更广泛的阿片类药物戒断症状可能有价值。
Zotero 插件